NGM BIOPHARMACEUTICALS INC Income Statement | Understand Stock

Login

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of operations

In millions of USD; shares in millions, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Related party revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Interest income, net
Other expense, net
Benefit from income taxes
Net loss
Net loss per share, basic (in dollars per share)
Net loss per share, diluted (in dollars per share)
Weighted average shares used to compute net loss per share, basic (in shares)
Weighted average shares used to compute net loss per share, diluted (in shares)

Loading...

Comments